Alkermes plc. director Cato T. Laurencin reported routine equity compensation activity. He received 5,409 restricted stock units and 11,538 non-qualified stock options with a $36.98 exercise price. On the next day, 6,142 RSUs were exercised into ordinary shares and 1,475 shares were withheld to cover tax obligations, leaving him with 33,769 ordinary shares directly held.
Alkermes plc director Richard Gaynor reported an amended insider filing reflecting equity awards granted as compensation. He received a restricted stock unit award for 5,409 units, each representing a contingent right to receive one ordinary share.
He was also granted a non-qualified stock option for 11,538 ordinary shares with an exercise price of $36.98 per share, expiring on May 20, 2036. All shares subject to these awards vest, and for the option become exercisable, in full on the earlier of the one-year anniversary of the grant date or the issuer’s next annual general meeting of shareholders that occurs at least 50 weeks after the grant date. The amendment corrects previously misreported vesting terms.
Alkermes plc director Shane Cooke reported equity awards and corrected vesting terms for a prior grant. He received a restricted stock unit award covering 5,409 ordinary shares and a non-qualified stock option for 11,538 ordinary shares at an exercise price of $36.98 per share, expiring on May 20, 2036. The filing explains that both awards vest in full on the earlier of the one-year anniversary of the grant date or the next annual general meeting of shareholders that occurs at least 50 weeks after the grant date. An amendment clarifies that earlier vesting terms were reported incorrectly and confirms the correct schedule.
Alkermes plc. director Richard Gaynor reported routine equity compensation and related share movements. He exercised 6,142 restricted stock units into ordinary shares and had 1,475 shares withheld to cover tax obligations at $36.95 per share, leaving 35,751 ordinary shares directly held after the withholding.
Gaynor also received new awards on ordinary shares: 5,409 restricted stock units and 11,538 non-qualified stock options with a $36.98 exercise price. Both the new RSUs and options vest fully on May 20, 2027, and the option award is exercisable after vesting through May 20, 2036.
Alkermes plc director Shane Cooke reported routine equity compensation activity and related tax withholding. He exercised 6,142 restricted stock units into ordinary shares and had 3,207 shares withheld to cover tax obligations at a price of $36.95 per share, which is not an open-market sale.
Cooke also received new awards on May 20, 2026, including 5,409 restricted stock units and a non-qualified stock option for 11,538 ordinary shares with an exercise price of $36.98 per share, both vesting in full on May 20, 2027. Following these transactions, he holds 109,886 ordinary shares directly.
Alkermes plc reported results from its 2026 annual general meeting of shareholders. Investors approved amendments to the 2018 Stock Option and Incentive Plan, increasing the ordinary shares authorized for issuance under the plan by 5,900,000. The updated plan is filed as Exhibit 10.1.
Shareholders elected all nine director nominees for one-year terms, with each receiving over 135 million votes in favor in most cases. They also approved, in a non-binding advisory vote, the compensation of named executive officers and ratified the appointment of PricewaterhouseCoopers LLP as independent auditor, authorizing the Audit and Risk Committee to set its remuneration.
In addition, shareholders renewed the Board’s authority to allot and issue shares under Irish law and renewed authority to disapply statutory pre-emption rights. Overall, the meeting confirmed the company’s current board composition, executive pay program, equity incentive plan, and capital authorization framework.
ALKERMES PLC reported a Schedule 13G/A amendment showing T. Rowe Price Associates, Inc. beneficially owned 4,664,563 shares of Common Stock, representing 2.8% of the class as stated in the filing. The filing lists sole voting power of 4,650,687 shares and sole dispositive power of 4,664,563. The report is signed by Ellen York, Vice President, dated 05/15/2026.
Alkermes plc reported positive phase 3 topline results from the REVITALYZ study of once-nightly LUMRYZ in adults with idiopathic hypersomnia. LUMRYZ met the primary endpoint, showing statistically significant improvement in excessive daytime sleepiness versus placebo on the Epworth Sleepiness Scale (p<0.0001), and met key secondary endpoints PGI-C and IHSS with similar significance.
The safety profile in idiopathic hypersomnia was generally consistent with prior LUMRYZ data, with common adverse events including nausea, headache, anxiety, dizziness and vomiting. Alkermes plans to submit a supplemental New Drug Application to the U.S. FDA by the end of 2026, but under an existing settlement it cannot market LUMRYZ for idiopathic hypersomnia before March 1, 2028, even if approved.
Alkermes plc reported a quarterly net loss after completing a large acquisition. For the three months ended March 31, 2026, revenue rose to $392.9 million from $306.5 million, driven by higher product sales including LUMRYZ, which contributed $39.5 million after the Avadel Pharmaceuticals acquisition.
The company recorded a net loss of $66.5 million, or $0.40 per share, compared with net income of $22.5 million a year earlier, mainly due to higher R&D, selling, general and administrative costs, amortization of new intangibles, and increased interest expense tied to new debt.
Alkermes closed the Avadel deal for about $2.31 billion in total preliminary consideration, recognizing $513.0 million of goodwill and $1.79 billion of intangible assets. To fund the transaction, it drew $1.525 billion of new term loans, which increased total assets to $4.26 billion and reduced cash and cash equivalents to $351.6 million.
Alkermes plc reported strong top-line growth but a GAAP loss for Q1 2026 and raised its EBITDA outlook for the year. Total revenues rose to $392.9 million from $306.5 million, driven by proprietary net sales of $338.1 million, including LYBALVI $92.4 million, ARISTADA $93.8 million, VIVITROL $112.4 million and newly acquired LUMRYZ $39.5 million.
The company posted a GAAP net loss of $66.5 million versus GAAP net income of $22.5 million a year earlier, with EBITDA at $(30.1) million and Adjusted EBITDA improving to $80.3 million from $45.6 million. Alkermes closed its acquisition of Avadel Pharmaceuticals in February, using about $775 million of cash and entering into $1.525 billion of term loans due 2031, leaving cash, cash equivalents, restricted cash and investments at $538.2 million versus $1.32 billion at year-end 2025.
For 2026, total revenue guidance of $1.73–$1.84 billion is unchanged, but GAAP net loss expectations improved to $70–$90 million and EBITDA guidance increased to $105–$135 million, while Adjusted EBITDA remains targeted at $370–$410 million. The outlook assumes VIVITROL net sales of $460–$480 million, LYBALVI $380–$400 million, ARISTADA $365–$385 million and LUMRYZ $315–$335 million.